For European-manufactured adenoviral vector programs, SK pharmteco, Exothera, and Advent Bioservices lead CDMO Signal's ranking of adenoviral vector CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 8 scored adenoviral vector CDMOs to 4 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.
Adenoviral vector CDMOs make replication-deficient adenovirus for gene therapy and vaccines, using producer cell lines (e.g. HEK293), suspension bioreactors, and chromatographic purification. The platform reaches high titers, which suits vaccine-scale demand.
Selecting an adenoviral CDMO turns on serotype and producer-line experience, suspension scale, full/empty particle control, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
#
CDMO
Signal Score
Quality
FDA · GMP
Capacity
Programs
1
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Confirm experience with your serotype (Ad5 and others) and producer cell line, and whether the process is suspension-adapted for scale.
Scale & titer
Adenovirus reaches high titers for vaccine-scale demand. Match validated bioreactor scale to your dose and volume.
Particle quality
Full/empty particle ratio and aggregate control affect potency and safety. Ask about the analytics package.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
EMA and MHRA regulatory considerations for European-manufactured programs
European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.
QP release requirements and how they affect CDMO selection
Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.
Which European CDMOs also cover FDA (US) regulatory geography?
European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.
By CDMO Signal's independent Signal Score, the top-ranked Adenoviral Vector CDMOs include SK pharmteco, Exothera, Advent Bioservices. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Adenoviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 0 Adenoviral Vector CDMOs with FDA inspection records and 10 EMA/MHRA GMP certificates across the group.
What should I look for in an adenoviral vector CDMO?
Confirm serotype and producer-line experience, a suspension process at your required scale, strong particle-quality analytics, and a clean FDA and EMA/MHRA record.
How is adenoviral vector manufacturing different from AAV?
Both are non-enveloped viral vectors made in HEK293-type lines, but adenovirus is larger and drives strong transient expression (suiting vaccines), while AAV is the workhorse for durable in vivo gene therapy.